Showing results (231-240 of 280) with videos related to
Sort By:
Pageof 28
British Journal of Haematology|July 21, 2018
Low incidence of symptomatic osteonecrosis after allogeneic HSCT in children with high-risk or relapsed ALL - results of the ALL-SCT 2003 trialMichaela Kuhlen, Peter Bader, Martin Sauer, et al.Haematologica|February 13, 2016
Risk assessment of relapse by lineage-specific monitoring of chimerism in children undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemiaSandra Preuner, Christina Peters, Ulrike Pötschger, et al.Haematologica|February 2, 2019
Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 studyCarmelo Rizzari, Claudia Lanvers-Kaminsky, Maria Grazia Valsecchi, et al.Blood|February 16, 2010
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 studyValentino Conter, Claus R Bartram, Maria Grazia Valsecchi, et al.EMBO Molecular Medicine|August 6, 2020
Chromatin accessibility landscape of pediatric T-lymphoblastic leukemia and human T-cell precursorsBüşra Erarslan-Uysal, Joachim B Kunz, Tobias Rausch, et al.Blood Advances|April 10, 2024
Development of combination therapies with BTK inhibitors and dasatinib to treat CNS-infiltrating E2A-PBX1+/preBCR+ ALLGaia Gentile, Teresa Poggio, Antonella Catalano, et al.Lancet (London, England)|September 23, 2008
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndromeDani Bercovich, Ithamar Ganmore, Linda M Scott, et al.The Lancet. Haematology|December 28, 2020
Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort studyMonique L den Boer, Gunnar Cario, Anthony V Moorman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2017
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000)Martin Schrappe, Kirsten Bleckmann, Martin Zimmermann, et al.Blood|February 19, 2016
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000Anja Möricke, Martin Zimmermann, Maria Grazia Valsecchi, et al.Pageof 28